Masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib
 
Status Suspended
Process STA
Topic area
  • Cancer
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Project manager:

Jeremy Powell

Technical Lead: Ahmed Elsada

Consultees

Manufacturers/sponsors AB Science (masitinib)
Others Department of Health
  NHS Leeds South and East CCG
  NHS England
  NHS Telford & Wrekin CCG
  Welsh Government
Patient/carer groups Afiya Trust
  Beating Bowel Cancer
  Black Health Agency
  Bladder and Bowel Foundation
  Bowel Cancer Information (formerly Lynn’s Bowel Cancer Campaign)
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  Equalities National Council
  GIST Support UK
  Helen Rollason Cancer Charity
  Independent Cancer Patient’s Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  Muslim Health Network
  Ochre
  Oesophageal Patients Association
  Rarer Cancers Foundation
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Association for Services to the Elderly
  British Association of Surgical Oncology
  British Geriatric Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Network Pharmacists Forum
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Health Forum
  United Kingdom Clinical Pharmacy Association
  United Kingdom Oncology Nursing Society

Commentators

Associated Guideline Groups National Collaborating Centre for Cancer
Associated Public Health Groups Public Health England
  Public Health Wales NHS Trust
Comparator manufacturer(s) Pfizer (sunitinib)
Evidence Review Group Aberdeen HTA Group
  National Institute for Health Research Health Technology Assessment Programme
General Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Commissioning Support Appraisals Service
  Department of Health,Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Bowel & Cancer Research
  Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  CORE (Digestive Disorders Foundation)
  Health Research Authority
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Research Institute for the Care of Older People

Timeline

Key events during the development of the guidance:

Date Update
22 July 2014 We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib.
20 February 2014 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance